University of Michigan

Jing Deng

Jolanta Grembecka

Tomasz Cierpicki

Szymon Klossowski

Hao Li

EunGi Kim

Hongzhi Miao

Trupta Purohit

Dong Chen

Dmitry Borkin

Deanna Montgomery

David Rogawski

Zhuang Jin

Marta Krotoska

Jin Zhuang

Marta Szewczyk

Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

ASH1L degraders and methods of treatment therewith

Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

ASH1L inhibitors and methods of treatment therewith

Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Growing community of inventors

Ann Arbor, MI, United States of America

Jing Deng